Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
The company expects to report topline data from the study in the summer of 2020.
Read MoreSelect Page
Posted by Invest In Weed | Nov 18, 2019
The company expects to report topline data from the study in the summer of 2020.
Read MorePosted by Invest In Weed | Nov 11, 2019
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE.
Read MorePosted by Invest In Weed | Oct 14, 2019
Patient enrollment increased approximately 20% to maintain >90% statistical power.
Read MorePosted by Invest In Weed | Sep 25, 2019
The recent update confirmed Goldman’s original research recommendations.
Read MorePosted by Invest In Weed | Sep 16, 2019
The survey is part of a pre-marketing campaign of PURA’s new CBD Infused beer, coffee and tea beverages.
Read MoreGet stock alerts, news & related alerts straight to your inbox!